Combined IFN-γ and retinoic acid treatment targets the N-Myc/Max/Mad1 signaling pathway and represses expression of the N-Myc/Mad1 target genes ornithine decarboxylase and hTERT, indicating that this combination strategy may have therapeutic benefits in targeting N-Myc function in high-risk, N-Myc-amplified neuroblastoma patients [39]. This evidence concerns the gene MYCN and neuroblastoma.